LABELS · d172c0d5-b118-4433-92bd-05214976dd8f

Orapred ODT

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-06-03
Captured: 2026-09-09T23:37:58.719708+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE Orapred ODT (prednisolone sodium phosphate orally disintegrating tablet) is indicated in the treatment of the following diseases or conditions: Orapred ODT is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation ( 1 ) for the treatment of certain endocrine conditions ( 1 ) for palliation of certain neoplastic conditions ( 1 ) 1.1 Allergic Conditions Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: Atopic dermatitis Drug hypersensitivity reactions Seasonal or perennial allergic rhinitis Serum sickness 1.2 Dermatologic Diseases Bullous dermatitis herpetiformis Contact dermatitis Exfoliative erythroderma Mycosis fungoides Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) 1.3 Endocrine Conditions Congenital adrenal hyperplasia Hypercalcemia of malignancy Nonsuppurative thyroiditis Primary or secondary adrenocortical insufficiency: hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable. 1.4 Gastrointestinal Diseases During acute episodes in: Crohn's Disease Ulcerative colitis 1.5 Hematologic Diseases Acquired (autoimmune) hemolytic anemia Diamond-Blackfan anemia Idiopathic thrombocytopenic purpura in adults Pure red cell aplasia Secondary thrombocytopenia in adults 1.6 Neoplastic Conditions For the treatment of: Acute leukemia Aggressive lymphomas 1.7 Nervous System Conditions Acute exacerbations of multiple sclerosis Cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury 1.8 Ophthalmic Conditions Sympathetic ophthalmia Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids 1.9 Conditions Related to Organ Transplantation Acute or chronic solid organ rejection 1.10 Pulmonary Diseases Acute exacerbations of chronic obstructive pulmonary disease (COPD) Allergic bronchopulmonary aspergillosis Aspiration pneumonitis Asthma Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Hypersensitivity pneumonitis Idiopathic bronchiolitis obliterans with organizing pneumonia Idiopathic eosinophilic pneumonias Idiopathic pulmonary fibrosis Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics Symptomatic sarcoidosis 1.11 Renal Conditions To induce a diuresis or remission of proteinuria in nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 1.12 Rheumatologic Conditions As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: Acute gouty arthritis During an exacerbation or as maintenance therapy in selected cases of: Ankylosing spondylitis Dermatomyositis /polymyositis Polymyalgia rheumatica/temporal arteritis Psoriatic arthritis Relapsing polychondritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) Sjogren's syndrome Systemic lupus erythematosus Vasculitis 1.13 Specific Infectious Diseases Trichinosis with neurologic or myocardial involvement Tuberculous meningitis with subarachnoid block or impending block, used concurrently with appropriate antituberculous chemotherapy

Full extracted label fields

application numbers

NDA021959

boxed warning exact

brand names

Orapred ODT

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e379543-c4cf-4e72-953b-db15b7f0c2a1

generic names

PREDNISOLONE SODIUM PHOSPHATE

d172c0d5-b118-4433-92bd-05214976dd8f

indications and usage exact

1 INDICATIONS AND USAGE Orapred ODT (prednisolone sodium phosphate orally disintegrating tablet) is indicated in the treatment of the following diseases or conditions: Orapred ODT is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation ( 1 ) for the treatment of certain endocrine conditions ( 1 ) for palliation of certain neoplastic conditions ( 1 ) 1.1 Allergic Conditions Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: Atopic dermatitis Drug hypersensitivity reactions Seasonal or perennial allergic rhinitis Serum sickness 1.2 Dermatologic Diseases Bullous dermatitis herpetiformis Contact dermatitis Exfoliative erythroderma Mycosis fungoides Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) 1.3 Endocrine Conditions Congenital adrenal hyperplasia Hypercalcemia of malignancy Nonsuppurative thyroiditis Primary or secondary adrenocortical insufficiency: hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable. 1.4 Gastrointestinal Diseases During acute episodes in: Crohn's Disease Ulcerative colitis 1.5 Hematologic Diseases Acquired (autoimmune) hemolytic anemia Diamond-Blackfan anemia Idiopathic thrombocytopenic purpura in adults Pure red cell aplasia Secondary thrombocytopenia in adults 1.6 Neoplastic Conditions For the treatment of: Acute leukemia Aggressive lymphomas 1.7 Nervous System Conditions Acute exacerbations of multiple sclerosis Cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury 1.8 Ophthalmic Conditions Sympathetic ophthalmia Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids 1.9 Conditions Related to Organ Transplantation Acute or chronic solid organ rejection 1.10 Pulmonary Diseases Acute exacerbations of chronic obstructive pulmonary disease (COPD) Allergic bronchopulmonary aspergillosis Aspiration pneumonitis Asthma Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Hypersensitivity pneumonitis Idiopathic bronchiolitis obliterans with organizing pneumonia Idiopathic eosinophilic pneumonias Idiopathic pulmonary fibrosis Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics Symptomatic sarcoidosis 1.11 Renal Conditions To induce a diuresis or remission of proteinuria in nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 1.12 Rheumatologic Conditions As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: Acute gouty arthritis During an exacerbation or as maintenance therapy in selected cases of: Ankylosing spondylitis Dermatomyositis /polymyositis Polymyalgia rheumatica/temporal arteritis Psoriatic arthritis Relapsing polychondritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) Sjogren's syndrome Systemic lupus erythematosus Vasculitis 1.13 Specific Infectious Diseases Trichinosis with neurologic or myocardial involvement Tuberculous meningitis with subarachnoid block or impending block, used concurrently with appropriate antituberculous chemotherapy

indications and usage tables exact

is original packager

true

manufacturer names

Advanz Pharma (US) Corp.

matched search terms

lymphomas
leukemia
tumor
malignancy

package ndcs

59212-700-06
59212-700-48
59212-700-12
59212-701-06
59212-701-48
59212-701-02
59212-701-12
59212-702-06
59212-702-48
59212-702-12

product ndcs

59212-700
59212-701
59212-702

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Immunosuppression and Increased Risk of Infection ( 5.2 ) 3/2024

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

643123
643125
643127
647127
668658
668660

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00600.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 779
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Orapred ODT (prednisolone sodium phosphate orally disintegrating tablet) is indicated in the treatment of the following diseases or conditions: Orapred ODT is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation ( 1 ) for the treatment of certain endocrine conditions ( 1 ) for palliation of certain neoplastic conditions ( 1 ) 1.1 Allergic Conditions Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: Atopic dermatitis Dru
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 0

current approval status

not_reconciled

duplicate text group

dup-2dc8dd3d816be7888926

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-4de41e54feeaed3a4fa4

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

end: 209
end exclusive: true
exact text: is indicated in the treatment of the following diseases or conditions: Orapred ODT is a corticosteroid indicated
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 97

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 579
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Orapred ODT (prednisolone sodium phosphate orally disintegrating tablet) is indicated in the treatment of the following diseases or conditions: Orapred ODT is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation ( 1 ) for the treatment of certain endocrine conditions ( 1 ) for palliation of certain neoplastic conditions ( 1 )
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1062
end exclusive: true
exact text: rheumatologic, specific infectious diseases or conditions and organ transplantation ( 1 ) for the treatment of certain endocrine conditions ( 1 ) for palliation of certain neoplastic conditions ( 1 ) 1.1 Allergic Conditions Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: Atopic dermatitis Drug hypersensitivity reactions Seasonal or perennial allergic rhinitis Serum sickness 1.2 Dermatologic Diseases Bullous dermatitis herpetiformis Contact dermatitis Exfoliative erythroderma Mycosis fungoides Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) 1.3 Endocrine
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 380

current approval status

not_reconciled

duplicate text group

dup-da345aaed4e50f71a740

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-6767d6e821512cf32001

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

context exact
intractable to adequate trials of conventional treatment in adult and pediatric populations with: Atopic dermatitis Drug hype
kind
age
polarity
not_inferred
span
end
725
end exclusive
true
exact text
adult
label id
d172c0d5-b118-4433-92bd-05214976dd8f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start
720
context exact
e to adequate trials of conventional treatment in adult and pediatric populations with: Atopic dermatitis Drug hypersensitivity r
kind
age
polarity
not_inferred
span
end
739
end exclusive
true
exact text
pediatric
label id
d172c0d5-b118-4433-92bd-05214976dd8f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start
730

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 862
end exclusive: true
exact text: 1.1 Allergic Conditions Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: Atopic dermatitis Drug hypersensitivity reactions Seasonal or perennial allergic rhinitis Serum sickness
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 580

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1247
end exclusive: true
exact text: ractable to adequate trials of conventional treatment in adult and pediatric populations with: Atopic dermatitis Drug hypersensitivity reactions Seasonal or perennial allergic rhinitis Serum sickness 1.2 Dermatologic Diseases Bullous dermatitis herpetiformis Contact dermatitis Exfoliative erythroderma Mycosis fungoides Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) 1.3 Endocrine Conditions Congenital adrenal hyperplasia Hypercalcemia of malignancy Nonsuppurative thyroiditis Primary or secondary adrenocortical insufficiency: hydrocortisone or cortisone is the fi
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 663

current approval status

not_reconciled

duplicate text group

dup-185caa9e11d6a3404e21

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-b16623cd371409c0e342

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1047
end exclusive: true
exact text: 1.2 Dermatologic Diseases Bullous dermatitis herpetiformis Contact dermatitis Exfoliative erythroderma Mycosis fungoides Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome)
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 863

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1545
end exclusive: true
exact text: Serum sickness 1.2 Dermatologic Diseases Bullous dermatitis herpetiformis Contact dermatitis Exfoliative erythroderma Mycosis fungoides Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) 1.3 Endocrine Conditions Congenital adrenal hyperplasia Hypercalcemia of malignancy Nonsuppurative thyroiditis Primary or secondary adrenocortical insufficiency: hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable. 1.4 Gastrointestinal Diseases During acute episodes in: Crohn's Disease Ulcerative colitis 1.5 Hematologic Diseases Acquired (autoimmune) hemolytic anemia Diamond-Blackfan anemia Idiopathic thrombocy
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 848

current approval status

not_reconciled

duplicate text group

dup-575d993728780c1a271e

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-e99db20a812c3f6ff8d4

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1345
end exclusive: true
exact text: 1.3 Endocrine Conditions Congenital adrenal hyperplasia Hypercalcemia of malignancy Nonsuppurative thyroiditis Primary or secondary adrenocortical insufficiency: hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable.
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1048

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1636
end exclusive: true
exact text: thyroiditis Primary or secondary adrenocortical insufficiency: hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable. 1.4 Gastrointestinal Diseases During acute episodes in: Crohn's Disease Ulcerative colitis 1.5 Hematologic Diseases Acquired (autoimmune) hemolytic anemia Diamond-Blackfan anemia Idiopathic thrombocytopenic purpura in adults Pure red cell aplasia Secondary thrombocytopenia in adults 1.6 Ne
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1146

current approval status

not_reconciled

duplicate text group

dup-57f3a454daa8b47598ef

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-fbba04934d2f582847de

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1436
end exclusive: true
exact text: 1.4 Gastrointestinal Diseases During acute episodes in: Crohn's Disease Ulcerative colitis
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1346

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1829
end exclusive: true
exact text: is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable. 1.4 Gastrointestinal Diseases During acute episodes in: Crohn's Disease Ulcerative colitis 1.5 Hematologic Diseases Acquired (autoimmune) hemolytic anemia Diamond-Blackfan anemia Idiopathic thrombocytopenic purpura in adults Pure red cell aplasia Secondary thrombocytopenia in adults 1.6 Neoplastic Conditions For the treatment of: Acute leukemia Aggressive lymphomas 1.7 Nervous System Conditions Acute exacerbations of multiple sclerosis Cerebral edema associated with primary or m
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1237

current approval status

not_reconciled

duplicate text group

dup-d44f3a1aecfdd8a7c8e0

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-050f68c2a7f1bfa3403c

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

context exact
mond-Blackfan anemia Idiopathic thrombocytopenic purpura in adults Pure red cell aplasia Secondary thrombocytopenia in adults
kind
age
polarity
not_inferred
span
end
1570
end exclusive
true
exact text
adults
label id
d172c0d5-b118-4433-92bd-05214976dd8f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start
1564
context exact
adults Pure red cell aplasia Secondary thrombocytopenia in adults
kind
age
polarity
not_inferred
span
end
1629
end exclusive
true
exact text
adults
label id
d172c0d5-b118-4433-92bd-05214976dd8f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start
1623

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1629
end exclusive: true
exact text: 1.5 Hematologic Diseases Acquired (autoimmune) hemolytic anemia Diamond-Blackfan anemia Idiopathic thrombocytopenic purpura in adults Pure red cell aplasia Secondary thrombocytopenia in adults
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1437

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1913
end exclusive: true
exact text: olitis 1.5 Hematologic Diseases Acquired (autoimmune) hemolytic anemia Diamond-Blackfan anemia Idiopathic thrombocytopenic purpura in adults Pure red cell aplasia Secondary thrombocytopenia in adults 1.6 Neoplastic Conditions For the treatment of: Acute leukemia Aggressive lymphomas 1.7 Nervous System Conditions Acute exacerbations of multiple sclerosis Cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury 1.8 Ophthalmic Conditions Sympathet
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1430

current approval status

not_reconciled

duplicate text group

dup-ed05090eda02411bb27b

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-02bbed72fa7e83f28f24

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1713
end exclusive: true
exact text: 1.6 Neoplastic Conditions For the treatment of: Acute leukemia Aggressive lymphomas
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1630

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2077
end exclusive: true
exact text: fan anemia Idiopathic thrombocytopenic purpura in adults Pure red cell aplasia Secondary thrombocytopenia in adults 1.6 Neoplastic Conditions For the treatment of: Acute leukemia Aggressive lymphomas 1.7 Nervous System Conditions Acute exacerbations of multiple sclerosis Cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury 1.8 Ophthalmic Conditions Sympathetic ophthalmia Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids 1.9 Conditions Related to Organ Transplantation Acute or chronic so
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1514

current approval status

not_reconciled

duplicate text group

dup-e461d292cc1eb94e2c2e

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-c93d7ebbfcdd69f0eaf1

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

context exact
ultiple sclerosis Cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury
kind
biomarker
polarity
not_inferred
span
end
1850
end exclusive
true
exact text
metastatic brain tumor
label id
d172c0d5-b118-4433-92bd-05214976dd8f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start
1828
context exact
ultiple sclerosis Cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury
kind
stage_or_setting
polarity
not_inferred
span
end
1850
end exclusive
true
exact text
metastatic brain tumor
label id
d172c0d5-b118-4433-92bd-05214976dd8f
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start
1828

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1877
end exclusive: true
exact text: 1.7 Nervous System Conditions Acute exacerbations of multiple sclerosis Cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1714

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2209
end exclusive: true
exact text: Acute leukemia Aggressive lymphomas 1.7 Nervous System Conditions Acute exacerbations of multiple sclerosis Cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury 1.8 Ophthalmic Conditions Sympathetic ophthalmia Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids 1.9 Conditions Related to Organ Transplantation Acute or chronic solid organ rejection 1.10 Pulmonary Diseases Acute exacerbations of chronic obstructive pulmonary disease (COPD) Allergic bronchopulm
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1678

current approval status

not_reconciled

duplicate text group

dup-5f7ae5ea29876d8cd8a6

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-9edfa8649177ded24aab

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2009
end exclusive: true
exact text: 1.8 Ophthalmic Conditions Sympathetic ophthalmia Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1878

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2296
end exclusive: true
exact text: d with primary or metastatic brain tumor, craniotomy or head injury 1.8 Ophthalmic Conditions Sympathetic ophthalmia Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids 1.9 Conditions Related to Organ Transplantation Acute or chronic solid organ rejection 1.10 Pulmonary Diseases Acute exacerbations of chronic obstructive pulmonary disease (COPD) Allergic bronchopulmonary aspergillosis Aspiration pneumonitis Asthma Fulminating or disseminated pulmonary
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1810

current approval status

not_reconciled

duplicate text group

dup-5a9d4303ecbb854250ea

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-465bf6345a8b61881d2d

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2096
end exclusive: true
exact text: 1.9 Conditions Related to Organ Transplantation Acute or chronic solid organ rejection
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 2010

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2906
end exclusive: true
exact text: itions Sympathetic ophthalmia Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids 1.9 Conditions Related to Organ Transplantation Acute or chronic solid organ rejection 1.10 Pulmonary Diseases Acute exacerbations of chronic obstructive pulmonary disease (COPD) Allergic bronchopulmonary aspergillosis Aspiration pneumonitis Asthma Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Hypersensitivity pneumonitis Idiopathic bronchiolitis obliterans with organizing pneumonia Idiopathic eosinophilic pneumonias Idiopathic pulmonary fibrosis Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics Symptomatic sarcoidosis 1.11 Renal Conditions To induce a diuresis or remission of proteinuria in nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 1.12 Rheumatologic Conditions A
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 1897

current approval status

not_reconciled

duplicate text group

dup-152b5aee3aeedce9974d

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-32545c1e26898d915a3d

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2706
end exclusive: true
exact text: 1.10 Pulmonary Diseases Acute exacerbations of chronic obstructive pulmonary disease (COPD) Allergic bronchopulmonary aspergillosis Aspiration pneumonitis Asthma Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Hypersensitivity pneumonitis Idiopathic bronchiolitis obliterans with organizing pneumonia Idiopathic eosinophilic pneumonias Idiopathic pulmonary fibrosis Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics Symptomatic sarcoidosis
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 2097

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3074
end exclusive: true
exact text: ry fibrosis Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics Symptomatic sarcoidosis 1.11 Renal Conditions To induce a diuresis or remission of proteinuria in nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 1.12 Rheumatologic Conditions As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: Acute gouty arthritis During an exacerbation or as ma
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 2507

current approval status

not_reconciled

duplicate text group

dup-fd0cef9bdf696993874c

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-b9c2eb1dd41975b8ad6f

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2874
end exclusive: true
exact text: 1.11 Renal Conditions To induce a diuresis or remission of proteinuria in nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 2707

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3632
end exclusive: true
exact text: biotics Symptomatic sarcoidosis 1.11 Renal Conditions To induce a diuresis or remission of proteinuria in nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 1.12 Rheumatologic Conditions As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: Acute gouty arthritis During an exacerbation or as maintenance therapy in selected cases of: Ankylosing spondylitis Dermatomyositis /polymyositis Polymyalgia rheumatica/temporal arteritis Psoriatic arthritis Relapsing polychondritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) Sjogren's syndrome Systemic lupus erythematosus Vasculitis 1.13 Specific Infectious Diseases Trichinosis with neurologic or myocardial involvement Tuberculous meningitis with subarachnoid block or impending block, used concurrently with appropriate antituber
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 2675

current approval status

not_reconciled

duplicate text group

dup-bde2d2772f2a35dedbff

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-e62e707867561f6adbcb

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 3432
end exclusive: true
exact text: 1.12 Rheumatologic Conditions As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: Acute gouty arthritis During an exacerbation or as maintenance therapy in selected cases of: Ankylosing spondylitis Dermatomyositis /polymyositis Polymyalgia rheumatica/temporal arteritis Psoriatic arthritis Relapsing polychondritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) Sjogren's syndrome Systemic lupus erythematosus Vasculitis
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 2875

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · unclassified context

application numbers

NDA021959

brand names

Orapred ODT

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3651
end exclusive: true
exact text: psing polychondritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) Sjogren's syndrome Systemic lupus erythematosus Vasculitis 1.13 Specific Infectious Diseases Trichinosis with neurologic or myocardial involvement Tuberculous meningitis with subarachnoid block or impending block, used concurrently with appropriate antituberculous chemotherapy
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 3233

current approval status

not_reconciled

duplicate text group

dup-278792f6be0c0b8072bf

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-b1d7ae438ff6e95b074b

label id

d172c0d5-b118-4433-92bd-05214976dd8f

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 3651
end exclusive: true
exact text: 1.13 Specific Infectious Diseases Trichinosis with neurologic or myocardial involvement Tuberculous meningitis with subarachnoid block or impending block, used concurrently with appropriate antituberculous chemotherapy
label id: d172c0d5-b118-4433-92bd-05214976dd8f
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 1c9580d344d81ae0d7d2016f71af14bebd9e606dd7b0880cd718fbcc34bc14c0
start: 3433

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d172c0d5-b118-4433-92bd-05214976dd8f%22

spl effective date

2025-06-03

spl set id

1e379543-c4cf-4e72-953b-db15b7f0c2a1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice